Review



mouse anti pp53 s15  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc mouse anti pp53 s15
    Mouse Anti Pp53 S15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 3358 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pmc13039127-214-11-15?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 3358 article reviews
    mouse anti pp53 s15 - by Bioz Stars, 2026-06
    96/100 stars

    Images



    Similar Products

    96
    Cell Signaling Technology Inc mouse anti pp53 s15
    Mouse Anti Pp53 S15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pmc13039127-214-11-15?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    mouse anti pp53 s15 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc pp53 s15
    Pp53 S15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pmc12682131-10-0-5?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    pp53 s15 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc pp53
    Pp53, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pm41189087-45-38-43?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    pp53 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti pp53 ser15
    Anti Pp53 Ser15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pmc12559235-415-21-23?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    anti pp53 ser15 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc pp53 phospho p53
    Mechanisms of PD-L1 regulation in lung cancer. PD-L1 expression in tumor cells is regulated at multiple levels. The <t>p53–p21</t> axis can negatively influence PD-L1 transcription, while oncogenic pathways such as PI3K/AKT and JAK/STAT promote its up-regulation. Epigenetic mechanisms play a critical role: histone acetylation and methylation dynamically regulate chromatin accessibility, and DNA methylation (e.g., via DNMT1) can repress or activate PD-L1 transcription depending on context. Collectively, these mechanisms contribute to PD-L1-mediated immune evasion and tumor survival.
    Pp53 Phospho P53, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pmc12428147-3-0-3?v=Cell+Signaling+Technology+Inc
    Average 93 stars, based on 1 article reviews
    pp53 phospho p53 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    97
    Cell Signaling Technology Inc pp53 ser15 cell signaling
    Mechanisms of PD-L1 regulation in lung cancer. PD-L1 expression in tumor cells is regulated at multiple levels. The <t>p53–p21</t> axis can negatively influence PD-L1 transcription, while oncogenic pathways such as PI3K/AKT and JAK/STAT promote its up-regulation. Epigenetic mechanisms play a critical role: histone acetylation and methylation dynamically regulate chromatin accessibility, and DNA methylation (e.g., via DNMT1) can repress or activate PD-L1 transcription depending on context. Collectively, these mechanisms contribute to PD-L1-mediated immune evasion and tumor survival.
    Pp53 Ser15 Cell Signaling, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pmc10104783__41556_2023_1096_MOESM1_ESM-38-218-220?v=Cell+Signaling+Technology+Inc
    Average 97 stars, based on 1 article reviews
    pp53 ser15 cell signaling - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc rabbit anti pp53
    Mechanisms of PD-L1 regulation in lung cancer. PD-L1 expression in tumor cells is regulated at multiple levels. The <t>p53–p21</t> axis can negatively influence PD-L1 transcription, while oncogenic pathways such as PI3K/AKT and JAK/STAT promote its up-regulation. Epigenetic mechanisms play a critical role: histone acetylation and methylation dynamically regulate chromatin accessibility, and DNA methylation (e.g., via DNMT1) can repress or activate PD-L1 transcription depending on context. Collectively, these mechanisms contribute to PD-L1-mediated immune evasion and tumor survival.
    Rabbit Anti Pp53, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pm40588650-359-71-73?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    rabbit anti pp53 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc pp53 ser15
    MCC cell lines are highly sensitive to IMPDH inhibition (A) CellTiter-Glo viability assay of established MCCP cell lines treated with increasing dosages of MPA for 3 days. Line color identifies p53-wild type (blue) and p53-mutant (red) cell lines. Statistics represent lowest significance (highest p ) of any p53-wild type versus mutant comparisons at the specified dose. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. The IC 50 was calculated for each cell line. (B) CellTiter-Glo viability assay of WaGa and MKL-1 cell lines treated concurrently with MPA (1 μM) and guanosine (10 μM) for 3 days. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (C) CellTiter-Glo viability assay of PDCLs treated as in (A), with an additional dose of MPA (50 μM). Line coloring and statistical test are identical to (A); N = 3; mean ± SD. The IC 50 was calculated for each cell line. (D) CellTiter-Glo viability assay of PDCLs treated concurrently with MPA (5 μM) and guanosine (1 μM) for 3 days. N = 3; mean ± SD; statistical tests are identical to (B). (E) Immunoblot of WaGa cells treated with MPA (1 μM) and guanosine (10 μM) for 24 h. Representative of 3 independent experiments. (F) Immunoblot of MKL-1 cells treated with MPA (1 μM) and guanosine (10 μM) for 3 days. Representative of 3 independent experiments. For panels E and F, total p53 is a reblot of the <t>pp53</t> blot after stripping (see ) and p21 is a reblot of PUMA. (G) RT-qPCR analysis of p53-dependent gene activation in WaGa and MKL-1 cells treated with MPA (1 μM) and guanosine (10 μM) for 1 or 3 days, respectively. Genes were normalized to the geometric mean of β-actin and β-2-microglobulin via the ΔΔCt method. N = 3; mean ± SD; one-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (H) AV/PI staining of WaGa cells treated with MPA (1 μM) and guanosine (10 μM) for 2 days. N = 3; mean ± SD; statistical tests are identical to (G). See also G and S1H.
    Pp53 Ser15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/pmc12148403-3-0-3?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    pp53 ser15 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti pp53 s15
    MCC cell lines are highly sensitive to IMPDH inhibition (A) CellTiter-Glo viability assay of established MCCP cell lines treated with increasing dosages of MPA for 3 days. Line color identifies p53-wild type (blue) and p53-mutant (red) cell lines. Statistics represent lowest significance (highest p ) of any p53-wild type versus mutant comparisons at the specified dose. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. The IC 50 was calculated for each cell line. (B) CellTiter-Glo viability assay of WaGa and MKL-1 cell lines treated concurrently with MPA (1 μM) and guanosine (10 μM) for 3 days. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (C) CellTiter-Glo viability assay of PDCLs treated as in (A), with an additional dose of MPA (50 μM). Line coloring and statistical test are identical to (A); N = 3; mean ± SD. The IC 50 was calculated for each cell line. (D) CellTiter-Glo viability assay of PDCLs treated concurrently with MPA (5 μM) and guanosine (1 μM) for 3 days. N = 3; mean ± SD; statistical tests are identical to (B). (E) Immunoblot of WaGa cells treated with MPA (1 μM) and guanosine (10 μM) for 24 h. Representative of 3 independent experiments. (F) Immunoblot of MKL-1 cells treated with MPA (1 μM) and guanosine (10 μM) for 3 days. Representative of 3 independent experiments. For panels E and F, total p53 is a reblot of the <t>pp53</t> blot after stripping (see ) and p21 is a reblot of PUMA. (G) RT-qPCR analysis of p53-dependent gene activation in WaGa and MKL-1 cells treated with MPA (1 μM) and guanosine (10 μM) for 1 or 3 days, respectively. Genes were normalized to the geometric mean of β-actin and β-2-microglobulin via the ΔΔCt method. N = 3; mean ± SD; one-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (H) AV/PI staining of WaGa cells treated with MPA (1 μM) and guanosine (10 μM) for 2 days. N = 3; mean ± SD; statistical tests are identical to (G). See also G and S1H.
    Anti Pp53 S15, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pp53+ser15/10__1158_slash_2767___9764__crc___24___0506-141-82-83?v=Cell+Signaling+Technology+Inc
    Average 96 stars, based on 1 article reviews
    anti pp53 s15 - by Bioz Stars, 2026-06
    96/100 stars
      Buy from Supplier

    Image Search Results


    Mechanisms of PD-L1 regulation in lung cancer. PD-L1 expression in tumor cells is regulated at multiple levels. The p53–p21 axis can negatively influence PD-L1 transcription, while oncogenic pathways such as PI3K/AKT and JAK/STAT promote its up-regulation. Epigenetic mechanisms play a critical role: histone acetylation and methylation dynamically regulate chromatin accessibility, and DNA methylation (e.g., via DNMT1) can repress or activate PD-L1 transcription depending on context. Collectively, these mechanisms contribute to PD-L1-mediated immune evasion and tumor survival.

    Journal: Cancers

    Article Title: Regulation of PD-L1 Expression by SAHA-Mediated Histone Deacetylase Inhibition in Lung Cancer Cells

    doi: 10.3390/cancers17172919

    Figure Lengend Snippet: Mechanisms of PD-L1 regulation in lung cancer. PD-L1 expression in tumor cells is regulated at multiple levels. The p53–p21 axis can negatively influence PD-L1 transcription, while oncogenic pathways such as PI3K/AKT and JAK/STAT promote its up-regulation. Epigenetic mechanisms play a critical role: histone acetylation and methylation dynamically regulate chromatin accessibility, and DNA methylation (e.g., via DNMT1) can repress or activate PD-L1 transcription depending on context. Collectively, these mechanisms contribute to PD-L1-mediated immune evasion and tumor survival.

    Article Snippet: pp53 (Phospho-p53) , CST , 12571 , 1:1000.

    Techniques: Expressing, Methylation, DNA Methylation Assay

    MCC cell lines are highly sensitive to IMPDH inhibition (A) CellTiter-Glo viability assay of established MCCP cell lines treated with increasing dosages of MPA for 3 days. Line color identifies p53-wild type (blue) and p53-mutant (red) cell lines. Statistics represent lowest significance (highest p ) of any p53-wild type versus mutant comparisons at the specified dose. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. The IC 50 was calculated for each cell line. (B) CellTiter-Glo viability assay of WaGa and MKL-1 cell lines treated concurrently with MPA (1 μM) and guanosine (10 μM) for 3 days. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (C) CellTiter-Glo viability assay of PDCLs treated as in (A), with an additional dose of MPA (50 μM). Line coloring and statistical test are identical to (A); N = 3; mean ± SD. The IC 50 was calculated for each cell line. (D) CellTiter-Glo viability assay of PDCLs treated concurrently with MPA (5 μM) and guanosine (1 μM) for 3 days. N = 3; mean ± SD; statistical tests are identical to (B). (E) Immunoblot of WaGa cells treated with MPA (1 μM) and guanosine (10 μM) for 24 h. Representative of 3 independent experiments. (F) Immunoblot of MKL-1 cells treated with MPA (1 μM) and guanosine (10 μM) for 3 days. Representative of 3 independent experiments. For panels E and F, total p53 is a reblot of the pp53 blot after stripping (see ) and p21 is a reblot of PUMA. (G) RT-qPCR analysis of p53-dependent gene activation in WaGa and MKL-1 cells treated with MPA (1 μM) and guanosine (10 μM) for 1 or 3 days, respectively. Genes were normalized to the geometric mean of β-actin and β-2-microglobulin via the ΔΔCt method. N = 3; mean ± SD; one-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (H) AV/PI staining of WaGa cells treated with MPA (1 μM) and guanosine (10 μM) for 2 days. N = 3; mean ± SD; statistical tests are identical to (G). See also G and S1H.

    Journal: iScience

    Article Title: IMPDH inhibition induces DNA replication stress and ATR sensitivity in Merkel cell carcinoma

    doi: 10.1016/j.isci.2025.112567

    Figure Lengend Snippet: MCC cell lines are highly sensitive to IMPDH inhibition (A) CellTiter-Glo viability assay of established MCCP cell lines treated with increasing dosages of MPA for 3 days. Line color identifies p53-wild type (blue) and p53-mutant (red) cell lines. Statistics represent lowest significance (highest p ) of any p53-wild type versus mutant comparisons at the specified dose. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. The IC 50 was calculated for each cell line. (B) CellTiter-Glo viability assay of WaGa and MKL-1 cell lines treated concurrently with MPA (1 μM) and guanosine (10 μM) for 3 days. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (C) CellTiter-Glo viability assay of PDCLs treated as in (A), with an additional dose of MPA (50 μM). Line coloring and statistical test are identical to (A); N = 3; mean ± SD. The IC 50 was calculated for each cell line. (D) CellTiter-Glo viability assay of PDCLs treated concurrently with MPA (5 μM) and guanosine (1 μM) for 3 days. N = 3; mean ± SD; statistical tests are identical to (B). (E) Immunoblot of WaGa cells treated with MPA (1 μM) and guanosine (10 μM) for 24 h. Representative of 3 independent experiments. (F) Immunoblot of MKL-1 cells treated with MPA (1 μM) and guanosine (10 μM) for 3 days. Representative of 3 independent experiments. For panels E and F, total p53 is a reblot of the pp53 blot after stripping (see ) and p21 is a reblot of PUMA. (G) RT-qPCR analysis of p53-dependent gene activation in WaGa and MKL-1 cells treated with MPA (1 μM) and guanosine (10 μM) for 1 or 3 days, respectively. Genes were normalized to the geometric mean of β-actin and β-2-microglobulin via the ΔΔCt method. N = 3; mean ± SD; one-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (H) AV/PI staining of WaGa cells treated with MPA (1 μM) and guanosine (10 μM) for 2 days. N = 3; mean ± SD; statistical tests are identical to (G). See also G and S1H.

    Article Snippet: pp53 (Ser15) , Cell Signaling Technology , CAT# 9284; RRID: AB_331464.

    Techniques: Inhibition, Viability Assay, Mutagenesis, Western Blot, Stripping Membranes, Quantitative RT-PCR, Activation Assay, Staining

    Functional p53 enhances IMPDH inhibition-induced cytotoxicity but is not required for cytotoxicity in MCC (A) Immunoblot of WaGa cells with inducible dominant negative p53 (p53DD) or eGFP pretreated with DOX (1 μg/mL) for 24 h followed by MPA (1 μM) for an additional 24 h. Representative of 3 independent experiments. (B) Immunoblot of MKL-1 clonal p53 knockout (KO) or control (AANSV1 and NTC) cells treated with MPA (1 μM) for 3 days. Representative of 3 independent experiments. For panels A and B, total p53 is a reblot of pp53 and p21 is a reblot of PUMA. (C) CellTiter-Glo viability assay of WaGa cells pretreated with DOX (1 μg/mL) for 24 h followed by MPA (1 μM) for 3 days. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (D) AV/DAPI staining of WaGa cells treated as in (C) for 2 days. N = 3; mean ± SD; statistical tests are identical to (C). See also B and S2C. (E) CellTiter-Glo viability of clonal MKL-1 control and p53 KO cell lines treated with increasing dosages of MPA for 3 days. N = 3; mean ± SD. Statistical tests are identical to (C). No statistical significance was identified. The IC 50 was calculated for each cell line.

    Journal: iScience

    Article Title: IMPDH inhibition induces DNA replication stress and ATR sensitivity in Merkel cell carcinoma

    doi: 10.1016/j.isci.2025.112567

    Figure Lengend Snippet: Functional p53 enhances IMPDH inhibition-induced cytotoxicity but is not required for cytotoxicity in MCC (A) Immunoblot of WaGa cells with inducible dominant negative p53 (p53DD) or eGFP pretreated with DOX (1 μg/mL) for 24 h followed by MPA (1 μM) for an additional 24 h. Representative of 3 independent experiments. (B) Immunoblot of MKL-1 clonal p53 knockout (KO) or control (AANSV1 and NTC) cells treated with MPA (1 μM) for 3 days. Representative of 3 independent experiments. For panels A and B, total p53 is a reblot of pp53 and p21 is a reblot of PUMA. (C) CellTiter-Glo viability assay of WaGa cells pretreated with DOX (1 μg/mL) for 24 h followed by MPA (1 μM) for 3 days. N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (D) AV/DAPI staining of WaGa cells treated as in (C) for 2 days. N = 3; mean ± SD; statistical tests are identical to (C). See also B and S2C. (E) CellTiter-Glo viability of clonal MKL-1 control and p53 KO cell lines treated with increasing dosages of MPA for 3 days. N = 3; mean ± SD. Statistical tests are identical to (C). No statistical significance was identified. The IC 50 was calculated for each cell line.

    Article Snippet: pp53 (Ser15) , Cell Signaling Technology , CAT# 9284; RRID: AB_331464.

    Techniques: Functional Assay, Inhibition, Western Blot, Dominant Negative Mutation, Knock-Out, Control, Viability Assay, Staining

    Dual inhibition of IMPDH and ATR induces p53-independent replication catastrophe (A) Immunoblot of WaGa cells pre-induced with DOX (1 μg/mL) for 24 h to express p53DD or eGFP followed by treatment with MPA (1 μM) and berzosertib (250 nM) for an additional 24 h. Representative of 3 independent experiments. (B) Immunoblot of MKL-1 p53 KO or control (AAVS1) cells treated with MPA (1 μM) and berzosertib (250 nM) for 3 days. Representative of 3 independent experiments. For panels A and B, the total p53 blot is a reblot of pp53, the total KAP1 blot is a reblot of the pKAP1 blot, the total CHK1 blot is a reblot of pCHK1, and the total RPA32 blot is a reblot of pRPA32. (C) Flow cytometry analysis of chromatin-associated γH2AX and RPA32 in WaGa cells pre-induced and treated as in (A). Gating strategy for each defined population is shown. Images generated in FlowJo. Representative of 3 independent experiments. (D) Quantification of populations from (C). N = 3; mean ± SD. (E) Quantification of chromatin-associated CDC45 from WaGa cells treated as in (A). N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (F) Quantification of chromatin-associated PCNA from WaGa cells treated as in (A). N = 3; mean ± SD; statistical tests are identical to (E). (G) Quantification of WaGa single cells dual-positive for AV and DAPI prepared as in (A) but treated with inhibitors for 2 days. N = 3; mean ± SD; statistical tests are identical to (E).

    Journal: iScience

    Article Title: IMPDH inhibition induces DNA replication stress and ATR sensitivity in Merkel cell carcinoma

    doi: 10.1016/j.isci.2025.112567

    Figure Lengend Snippet: Dual inhibition of IMPDH and ATR induces p53-independent replication catastrophe (A) Immunoblot of WaGa cells pre-induced with DOX (1 μg/mL) for 24 h to express p53DD or eGFP followed by treatment with MPA (1 μM) and berzosertib (250 nM) for an additional 24 h. Representative of 3 independent experiments. (B) Immunoblot of MKL-1 p53 KO or control (AAVS1) cells treated with MPA (1 μM) and berzosertib (250 nM) for 3 days. Representative of 3 independent experiments. For panels A and B, the total p53 blot is a reblot of pp53, the total KAP1 blot is a reblot of the pKAP1 blot, the total CHK1 blot is a reblot of pCHK1, and the total RPA32 blot is a reblot of pRPA32. (C) Flow cytometry analysis of chromatin-associated γH2AX and RPA32 in WaGa cells pre-induced and treated as in (A). Gating strategy for each defined population is shown. Images generated in FlowJo. Representative of 3 independent experiments. (D) Quantification of populations from (C). N = 3; mean ± SD. (E) Quantification of chromatin-associated CDC45 from WaGa cells treated as in (A). N = 3; mean ± SD; two-way ordinary ANOVA corrected for multiple comparisons via Tukey post hoc test; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (F) Quantification of chromatin-associated PCNA from WaGa cells treated as in (A). N = 3; mean ± SD; statistical tests are identical to (E). (G) Quantification of WaGa single cells dual-positive for AV and DAPI prepared as in (A) but treated with inhibitors for 2 days. N = 3; mean ± SD; statistical tests are identical to (E).

    Article Snippet: pp53 (Ser15) , Cell Signaling Technology , CAT# 9284; RRID: AB_331464.

    Techniques: Inhibition, Western Blot, Control, Flow Cytometry, Generated